Nanopore sensing technology is fully scalable and the high-throughput, high-sample number PromethION is currently being prepared for release in the PromethION Early Access Programme. The transaction brings the total funds raised by Oxford Nanopore since its formation in 2005 to £351.0 million, which will endeavour to open a potential global annual opportunity estimated to exceed US$2bn. In continuing to invest in IP Group's portfolio companies, funds such as GT Healthcare are recognising both the unique nature of the intellectual property and long-term market potential being offered through IP Group's portfolio companies.